Disclosure of payments made to HCPs in Ireland
As part of our goal to be one of the most innovative, best performing and trusted healthcare companies in the world, we seek to meet society’s evolving expectations, bring greater transparency to an already well-regulated industry, and strengthen our relationships with Healthcare Professionals (HCPs), and Healthcare Organisations (HCOs) for future collaboration.
Cooperation between pharmaceutical companies, regulators, HCP, HCOs, and patients, is essential for the sustainable improvement of healthcare. These relationships have helped deliver numerous innovative new medicines and changed the way many diseases impact on our lives. HCPs have always been, and will always be, valuable partners for GSK. As experts in their field, they provide us with first hand scientific and medical knowledge and unique insights into patient care. This partnership is fundamental to the progression of medical science, helping to meet patient and public health needs.
Under the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code, from 2016 EFPIA member companies pledged to disclose the transfers of value they make to HCPs and HCOs in connection with prescription medicines, such as consultancy and speaker fees, on an individual named basis (aggregate by exception only). Transfers of value made to HCPs and HCOs for activities related to research and development are disclosed as an aggregate number.
Disclosure information is published annually (covering the previous year) on a public platform; either the company’s own website or, in some countries, a central platform combining data from different companies.
Our disclosures for Ireland
The link below will take you to our disclosures for Ireland in line with the EFPIA code and Irish Pharmaceutical Healthcare Association (IPHA) code, that we are making through IPHA.
Media enquiries: Please contact Claire Taaffe, Communications Director, GSK Ireland.
E-mail: email@example.com or Tel: +353 86 805 3251